Five top stories in cytopathology

Archives of Pathology and Laboratory Medicine

Volumn 137, Issue 7, 2013, Pages 894-906

  Fischer, Andrew H ^a   Benedict, Cynthia C ^b   Amrikachi, Mojgan ^c  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b DCL Medical Laboratories   (United States)

^c HOUSTON METHODIST HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL TRIAL (TOPIC); COST BENEFIT ANALYSIS; CYTODIAGNOSIS; ECHOGRAPHY; ECONOMICS; ENDOSCOPY; FEMALE; FINE NEEDLE ASPIRATION BIOPSY; GENE EXPRESSION PROFILING; GENETICS; HUMAN; LABORATORY DIAGNOSIS; MALE; METHODOLOGY; MOLECULAR DIAGNOSIS; MOLECULARLY TARGETED THERAPY; NEOPLASM; NUCLEOTIDE SEQUENCE; THYROID TUMOR;

BIOPSY, FINE-NEEDLE; CLINICAL TRIALS AS TOPIC; COST-BENEFIT ANALYSIS; CYTODIAGNOSIS; DNA MUTATIONAL ANALYSIS; ENDOSCOPY; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MALE; MOLECULAR DIAGNOSTIC TECHNIQUES; MOLECULAR TARGETED THERAPY; NEOPLASMS; SPECIMEN HANDLING; THYROID NEOPLASMS; ULTRASONOGRAPHY;

EID: 84879665100     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: 10.5858/arpa.2012-0258-SA     Document Type: Article

References (136)

1. Centeno BA. Diagnostic cytology of the biliary tract and pancreas. In: Odze RD, Goldblum JR, eds. Surgical Pathology of the GI Tract, Liver, Biliary Tract, and Pancreas. 2nd ed. Philadelphia, PA: Saunders Elsevier; 2009:797.
2. Istvanic S, Fischer AH, Banner BF, et al. Cell blocks of breast FNAs frequently allow diagnosis of invasion or histological classification of proliferative changes. Diagn Cytopathol. 2007;35(5):263-269.
3. Akalin A, Lu D, Woda B, Moss L, Fischer A. Rapid cell blocks improve accuracy of breast FNAs beyond that provided by conventional cell blocks regardless of immediate adequacy evaluation. Diagn Cytopathol. 2008;36(7): 523-529.
4. Wagner DG, Russell DK, Benson JM, Schneider AE, Hoda RS, Bonfiglio TA. CellientTM automated cell block versus traditional cell block preparation: a comparison of morphologic features and immunohistochemical staining. Diagn Cytopathol. 2011;39(10):730-736.
5. Nguyen NQ. Endoscopic ultrasound-guided fine needle core biopsy versus aspiration for gastrointestinal mass lesions: a randomized trial. ASCO Meet Abstr. 2012;30(4 suppl):161.
6. Levenson RM, Fornari A, Loda M. Multispectral imaging and pathology: seeing and doing more. Expert Opin Med Diagn. 2008;2(9):1067-1081.
7. Schmolze DB, Standley C, Fogarty KE, Fischer AH. Advances in microscopy techniques. Arch Pathol Lab Med. 2011;135(2):255-263.
8. Paull PE, Hyatt BJ, Wassef W, Fischer AH. Confocal laser endomicroscopy: a primer for pathologists. Arch Pathol Lab Med. 2011;135(10):1343-1348.
9. Fischer AH, Taysavang P, Weber C, Wilson K. Nuclear envelope organization in papillary thyroid carcinoma. Histol Histopathol. 2001;16(1):1-14.
10. Bussolati G. Proper detection of the nuclear shape: ways and significance. Rom J Morphol Embryol. 2008;49(4):435-439.
11. Bussolati G, Marchio C, Gaetano L, Lupo R, Sapino A. Pleomorphism of the nuclear envelope in breast cancer: a new approach to an old problem. J Cell Mol Med. 2008;12(1):209-218.
12. Crow EW, Crow JF. 100 years ago: Walter Sutton and the chromosome theory of heredity. Genetics. 2002;160(1):1-4.
13. Ried T. Homage to Theodor Boveri (1862-1915): Boveri's theory of cancer as a disease of the chromosomes, and the landscape of genomic imbalances in human carcinomas. Environ Mol Mutagen. 2009;50(8):593-601.
14. McClintock B. The relation of a particular chromosomal element to the development of the nucleoli in Zea mays. Cell Tissue Res. 1934;21(2):294-326.
15. Perry RP. The cellular sites of synthesis of ribosomal and 4s RNA. Proc Natl Acad Sci U S A. 1962;48(12):2179-2186.
16. Barr ML, Bertram EG. A morphological distinction between neurones of the male and female, and the behaviour of the nucleolar satellite during accelerated nucleoprotein synthesis. Nature. 1949;163(4148):30.
17. Gitschier J. The gift of observation: an interview with Mary Lyon. PLoS Genet. 2010;6(1):e1000813.
18. Brown SW. Heterochromatin. Science. 1966;151(709):417-425.
19. Weintraub H, Groudine M. Chromosomal subunits in active genes have an altered conformation. Science. 1976;193(4256):848-856.
20. Chalfie M, Tu Y, Euskirchen G, Ward WW, Prasher DC. Green fluorescent protein as a marker for gene expression. Science. 1994;263(5148):802-805.
21. Tsien RY. The green fluorescent protein. Annu Rev Biochem. 1998;67: 509-544.
22. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100(1): 57-70.
23. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-674.
24. Fischer AH, Zhao C, Li QK, et al. The cytologic criteria of malignancy. J Cell Biochem. 2010;110:975-811.
25. Fischer AH, Young KA, DeLellis RA. Incorporating the criteria of malignancy into the evolutionary framework for cancer. J Cell Biochem. 2004; 93:28-36.
26. Fischer AH, Bond JA, Taysavang P, Battles OE, Wynford-Thomas D. Papillary thyroid carcinoma oncogene (RET/PTC) alters the nuclear envelope and chromatin structure. Am J Pathol. 1998;153:1443-1450.
27. Fischer AH, Taysavang P, Jhiang SM. Nuclear envelope irregularity is induced by RET/PTC during interphase. Am J Pathol. 2003;163(3):1091-1100.
28. Knauf JA, Ma X, Smith EP, et al. Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation. Cancer Res. 2005;65(10):4238-4245.
29. Jenuwein T, Allis CD. Translating the histone code. Science. 2001; 293(5532):1074-1080.
30. Cobb CJ, Raza AS. Obituary: "alas poor FNA of breast - we knew thee well!" Diagn Cytopathol. 2005;32(1):1-4.
31. Rusch VW. Mediastinoscopy: an obsolete procedure? J Thorac Cardiovasc Surg. 2011;142(6):1400-1402.
32. Cameron SEH, Andrade RS, Pambuccian SE. Endobronchial ultrasoundguided transbronchial needle aspiration cytology: a state of the art review. Cytopathology. 2010;21(1):6-26.
33. Ost DE, Ernst A, Lei X, et al. Diagnostic yield of endobronchial ultrasound-guided transbronchial needle aspiration. Chest. 2011;140(6):1557- 1566.
34. Medford AR, Bennett JA, Free CM, Agrawal S. Mediastinal staging procedures in lung cancer: EBUS, TBNA and mediastinoscopy. Curr Opin Pulm Med. 2009;15(4):334-342.
35. Yasufuku K, Pierre A, Darling G, et al. A prospective controlled trial of endobronchial ultrasound-guided transbronchial needle aspiration compared with mediastinoscopy for mediastinal lymph node staging of lung cancer. J Thorac Cardiovasc Surg. 2011;142(6):1393-1400.
36. Harewood GC, Pascual J, Raimondo M, et al. Economic analysis of combined endoscopic and endobronchial ultrasound in the evaluation of patients with suspected non-small cell lung cancer. Lung Cancer. 2010;67(3): 366-371.
37. Davey DD, Neal MH. Coding changes in the United States front and center: implications for cytopathology. Cancer Cytopathol. 2011;119(5):310-314.
38. Nayak A, Sugrue C, Koenig S, Wasserman PG, Hoda S, Morgenstern NJ. Endobronchial ultrasound-guided transbronchial needle aspirate (EBUS-TBNA): a proposal for on-site adequacy criteria. Diagn Cytopathol. 2012;40(2):128-137.
39. Bardales RH, Stelow EB, Mallery S, Lai R, Stanley MW. Review of endoscopic ultrasound-guided fine-needle aspiration cytology. Diagn Cytopathol. 2006;34(2):140-175.
40. Tambouret R, Geisinger KR, Powers CN, et al. The clinical application and cost analysis of fine-needle aspiration biopsy in the diagnosis of mass lesions in sarcoidosis. Chest. 2000;117(4):1004-1011.
41. Du Rand IA, Barber PV, Goldring J, et al. British Thoracic Society guideline for advanced diagnostic and therapeutic flexible bronchoscopy in adults. Thorax. 2011;66(suppl 3):iii1-iii21.
42. Kopelman Y, Marmor S, Ashkenazi I, Fireman Z. Value of EUS-FNA cytological preparations compared with cell block sections in the diagnosis of pancreatic solid tumours. Cytopathology. 2011;22(3):174-178.
43. Ishida T, Asano F, Yamazaki K, et al. Virtual bronchoscopic navigation combined with endobronchial ultrasound to diagnose small peripheral pulmonary lesions: a randomised trial. Thorax. 2011;66(12):1072-1077.
44. Schwarz Y, Mehta AC, Ernst A, et al. Electromagnetic navigation during flexible bronchoscopy. Respiration. 2003;70(5):516-522.
45. Schwarz Y, Greif J, Becker HD, Ernst A, Mehta A. Real-time electromagnetic navigation bronchoscopy to peripheral lung lesions using overlaid CT images. Chest. 2006;129(4):988-994.
46. Chang MC, Crystal P, Colgan TJ. The evolving role of axillary lymph node fine-needle aspiration in the management of carcinoma of the breast. Cancer Cytopathol. 2011;119(5):328-334.
47. Boughey J, Moriarty J, Degnim A, Gregg M, Egginton J, Long K. Cost modeling of preoperative axillary ultrasound and fine-needle aspiration to guide surgery for invasive breast cancer. Ann Surg Oncol. 2010;17(4):953-958.
48. Rao R, Lilley L, Andrews V, Radford L, Ulissey M. Axillary staging by percutaneous biopsy: sensitivity of fine-needle aspiration versus core needle biopsy. Ann Surg Oncol. 2009;16(5):1170-1175.
49. Varadarajulu S, Fraig M, Schmulewitz N, et al. Comparison of EUSguided 19-gauge Trucut needle biopsy with EUS-guided fine-needle aspiration. Endoscopy. 2004;36(5):397-401.
50. Gerke H, Rizk MK, Vanderheyden AD, Jensen CS. Randomized study comparing endoscopic ultrasound-guided Trucut biopsy and fine needle aspiration with high suction. Cytopathology. 2010;21(1):44-51.
51. Dalal SS, Pitelka-Zengou L, Paintal AS, et al. Assessment of on-site evaluation (OSE) and diagnostic yield of EUS-fine needle aspiration (FNA) versus EUS-guided needle core biopsy using EchoTip ProCore (ETP) device. Mod Pathol. 2012;25(S2):86A.
52. Nosotti M, Tosi D, Palleschi A, Ferrero S, Rosso L. Transbronchial needle aspiration under direct endobronchial ultrasound guidance of PET-positive isolated mediastinal adenopathy in patients with previous malignancy. Surg Endosc. 2009;23(6):1356-1359.
53. Mitsudomi T, Yatabe Y. Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci. 2007;98(12): 1817-1824.
54. Cagle PT, Dacic S. Lung cancer and the future of pathology. Arch Pathol Lab Med. 2011;135(3):293-295.
55. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010;363(18):1693-1703.
56. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011; 364(26):2507-2516.
57. Rekhtman N, Brandt SM, Sigel CS, et al. Suitability of thoracic cytology for new therapeutic paradigms in non-small cell lung carcinoma: high accuracy of tumor subtyping and feasibility of EGFR and KRAS molecular testing. J Thorac Oncol. 2011;6(3):451-458.
58. Santis G, Angell R, Nickless G, et al. Screening for EGFR and KRAS mutations in endobronchial ultrasound derived transbronchial needle aspirates in non-small cell lung cancer using COLD-PCR. PLoS ONE. 2011;6(9):e25191.
59. Ladd AC, O'Sullivan-Mejia E, Lea T, et al. Preservation of fine-needle aspiration specimens for future use in RNA-based molecular testing. Cancer Cytopathol. 2011;119(2):103-110.
60. Sanati S, Lu DW, Schmidt E, Perry A, Dehner LP, Pfeifer JD. Cytologic diagnosis of Ewing sarcoma/peripheral neuroectodermal tumor with paired prospective molecular genetic analysis. Cancer. 2007;111(3):192-199.
61. Betz BL, Roh MH, Weigelin HC, et al. The application of molecular diagnostic studies interrogating EGFR and KRAS mutations to stained cytologic smears of lung carcinoma. Am J Clin Pathol. 2011;136(4):564-571.
62. da Cunha Santos G, Saieg MA, Geddie W, Leighl N. EGFR gene status in cytological samples of nonsmall cell lung carcinoma. Cancer Cytopathol. 2011; 119(2):80-91.
63. Billah S, Stewart J, Staerkel G, Chen S, Gong Y, Guo M. EGFR and KRAS mutations in lung carcinoma: molecular testing by using cytology specimens. Cancer Cytopathol. 2011;119(2):111-117.
64. Bozzetti C, Personeni N, Nizzoli R, et al. HER-2/neu amplification by fluorescence in situ hybridization in cytologic samples from distant metastatic sites of breast carcinoma. Cancer. 2003;99(5):310-315.
65. Abati A, Sanford JS, Fetsch P, Marincola FM, Wolman SR. Fluorescence in situ hybridization (FISH): a user's guide to optimal preparation of cytologic specimens. Diagn Cytopathol. 1995;13(5):486-492.
66. Gong X, Lu X, Wu X, et al. Role of bone marrow imprints in haematological diagnosis: a detailed study of 3781 cases. Cytopathology. 2012;23(2):86-95.
67. Kipp BR, Stadheim LM, Halling SA, et al. A comparison of routine cytology and fluorescence in situ hybridization for the detection of malignant bile duct strictures. Am J Gastroenterol. 2004;99(9):1675-1681.
68. Moelans CB, Oostenrijk D, Moons MJ, van Diest PJ. Formaldehyde substitute fixatives: effects on nucleic acid preservation. J Clin Pathol. 2011; 64(11):960-967.
69. Cohen MB, Weydert JA. Neoplastic pulmonary cytology: why all the fuss over "NSCLC"? Cancer Cytopathol. 2011;119(1):3-4.
70. Zakowski MF. Fine-needle aspiration cytology of tumors: diagnostic accuracy and potential pitfalls. Cancer Invest. 1994;12(5):505-515.
71. Sigel CS, Moreira AL, Travis WD, et al. Subtyping of non-small cell lung carcinoma: a comparison of small biopsy and cytology specimens. J Thorac Oncol. 2011;6(11):1849-1856.
72. Fischer AH, Cibas ES, Howell LP, et al. Role of cytology in the management of non-small-cell lung cancer. J Clin Oncol. 2011;29(24):3331-3332.
73. Nizzoli R, Tiseo M, Gelsomino F, et al. Accuracy of fine needle aspiration cytology in the pathological typing of non-small cell lung cancer. J Thorac Oncol. 2011;6(3):489-493.
74. Wu M, Szporn AH, Zhang D, et al. Cytology applications of p63 and TTF-1 immunostaining in differential diagnosis of lung cancers. Diagn Cytopathol. 2005;33(4):223-227.
75. Vysis LSI ALK Break Apart Rearrangement Probes. Abbott Molecular Web site. http://www.abbottmolecular.com/us/products/oncology/fish/lung-cancer/ vysis-lsi-alk-dual-color-break-apart-rearrangement-probe.html#indications- andlimitations. Accessed August 4, 2012.
76. Vincek V, Nassiri M, Nadji M, Morales AR. A tissue fixative that protects macromolecules (DNA, RNA, and protein) and histomorphology in clinical samples. Lab Invest. 2003;83(10):1427-1435.
77. Stanta G, Mucelli SP, Petrera F, Bonin S, Bussolati G. A novel fixative improves opportunities of nucleic acids and proteomic analysis in human archive's tissues. Diagn Mol Pathol. 2006;15(2):115-123.
78. Bellet V, Boissière F, Bibeau F, et al. Proteomic analysis of RCL2 paraffinembedded tissues. J Cell Mol Med. 2008;12(5b):2027-2036.
79. Mueller C, Edmiston KH, Carpenter C, et al. One-step preservation of phosphoproteins and tissue morphology at room temperature for diagnostic and research specimens. PLoS ONE. 2011;6(8):e23780.
80. Gilbert MTP, Haselkorn T, Bunce M, et al. The isolation of nucleic acids from fixed, paraffin-embedded tissues - which methods are useful when? PLoS ONE. 2007;2(6):e537.
81. Killian JK, Walker RL, Suuriniemi M, et al. Archival fine-needle aspiration cytopathology (FNAC) samples: untapped resource for clinical molecular profiling. J Mol Diagn. 2010;12(6):739-745.
82. Srinivasan M, Sedmak D, Jewell S. Effect of fixatives and tissue processing on the content and integrity of nucleic acids. Am J Pathol. 2002;161(6):1961-1971.
83. Dotti I, Bonin S, Basili G, et al. Effects of formalin, methacarn, and fineFIX fixatives on RNA preservation. Diagn Mol Pathol. 2010;19(2):112-122.
84. Kothmaier H, Rohrer D, Stacher E, Quehenberger F, Becker K-F, Popper HH. Comparison of formalin-free tissue fixatives: a proteomic study testing their application for routine pathology and research. Arch Pathol Lab Med. 2011; 135(6):744-752.
85. Commission of Inquiry on Hormone Receptor Testing Web site. http://www.cihrt.nl.ca/. Accessed August 3, 2012.
86. Investigation and Findings. Commission of Inquiry on Hormone Receptor Testing; vol 1. http://www.cihrt.nl.ca/Final%20Report/ Volume%201%20Investigation%20and%20Findings.pdf. Accessed August 3, 2012.
87. Cox ML, Schray CL, Luster CN, et al. Assessment of fixatives, fixation, and tissue processing on morphology and RNA integrity. Exp Mol Pathol. 2006;80(2): 183-191.
88. Aisner DL, Deshpande C, Baloch Z, et al. Evaluation of EGFR mutation status in cytology specimens: an institutional experience [published online ahead of print November 18, 2011]. Diagn Cytopathol. doi:10.1002/dc.21851.
89. World Health Organization IARC. Formaldehyde, 2-Butoxyethanol and 1-tert-Butoxypropan-2-ol. Lyon, France: World Health Organization IARC; 2006. Monographs on the Evaluation of Carcinogenic Risks to Humans: Summary of Data Reported and Evaluation; vol 16.
90. Jennings L, Van Deerlin VM, Gulley ML. Recommended principles and practices for validating clinical molecular pathology tests. Arch Pathol Lab Med. 2009;133(5):743-755.
91. Kurtycz DF, Logrono R, Leopando M, Slattery A, Inhorn SL. Immunocytochemistry controls using cell culture. Diagn Cytopathol. 1997;17(1):74-79.
92. Miller JM, Hamburger JI, Kini S. Diagnosis of thyroid nodules: use of fineneedle aspiration and needle biopsy. JAMA. 1979;241(5):481-484.
93. Yassa L, Cibas ES, Benson CB, et al. Long-term assessment of a multidisciplinary approach to thyroid nodule diagnostic evaluation. Cancer Cytopathol. 2007;111(6):508-516.
94. Yang J, Schnadig V, Logrono R, Wasserman PG. Fine-needle aspiration of thyroid nodules: a study of 4703 patients with histologic and clinical correlations. Cancer Cytopathol. 2007;111(5):306-315.
95. Pacini F, Schlumberger M, Dralle H, et al. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol. 2006;154(6):787-803.
96. Khalid AN, Hollenbeak CS, Quraishi SA, Fan CY, Stack BC Jr. The costeffectiveness of iodine 131 scintigraphy, ultrasonography, and fine-needle aspiration biopsy in the initial diagnosis of solitary thyroid nodules. Arch Otolaryngol Head Neck Surg. 2006;132(3):244-250.
97. Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19(11):1167-1214.
98. Lansford CD, Teknos TN. Evaluation of the thyroid nodule. Cancer Control. 2006;13(2):89-98.
99. Li H, Robinson KA, Anton B, Saldanha IJ, Ladenson PW. Costeffectiveness of a novel molecular test for cytologically indeterminate thyroid nodules. J Clin Endocrinol Metab. 2011:E1719-E1726.
100. Thyroid cancer. National Cancer Institute Web site. http://www.cancer. gov/cancertopics/types/thyroid. Accessed August 4, 2012.
101. Cibas ES, Ali SZ. The Bethesda system for reporting thyroid cytopathology. Am J Clin Pathol. 2009;132(5):658-665.
102. Baloch ZW, Cibas ES, Clark DP, et al. The National Cancer Institute Thyroid fine needle aspiration state of the science conference: a summation. Cytojournal. 2008;5(6).
103. Filie AC, Asa SL, Geisinger KR, et al. Utilization of ancillary studies in thyroid fine needle aspirates: a synopsis of the National Cancer Institute Thyroid Fine Needle Aspiration State of the Science Conference. Diagn Cytopathol. 2008; 36(6):438-441.
104. Yip L, Farris C, Kabaker AS, et al. Cost impact of molecular testing for indeterminate thyroid nodule fine needle aspiration biopsies. J Clin Endocrinol Metab. 2012;97(6):1905-1912.
105. Borget I, Vielh P, Leboulleux S, et al. Assessment of the cost of fine-needle aspiration cytology as a diagnostic tool in patients with thyroid nodules. Am J Clin Pathol. 2008;129(5):763-771.
106. Nikiforova MN, Chiosea SI, Nikiforov YE. MicroRNA expression profiles in thyroid tumors. Endocr Pathol. 2009;20(2):85-91.
107. Kitano M, Rahbari R, Patterson E, et al. Expression profiling of difficult-todiagnose thyroid histologic subtypes shows distinct expression profiles and identify candidate diagnostic microRNAs. Ann Surg Oncol. 2011;18(12):3443-3452.
108. Nikiforov YE, Steward DL, Robinson-Smith TM, et al. Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules. J Clin Endocrinol Metab. 2009;94(6):2092-2098.
109. Ohori NP, Nikiforova MN, Schoedel KE, et al. Contribution of molecular testing to thyroid fine-needle aspiration cytology of "follicular lesion of undetermined significance/atypia of undetermined significance." Cancer Cytopathol. 2010;118(1):17-23.
110. Cantara S, Capezzone M, Marchisotta S, et al. Impact of proto-oncogene mutation detection in cytological specimens from thyroid nodules improves the diagnostic accuracy of cytology. J Clin Endocrinol Metab. 2010;95(3):1365-1369.
111. Nikiforov YE, Ohori NP, Hodak SP, et al. Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: a prospective analysis of 1056 FNA samples. J Clin Endocrinol Metab. 2011;96(11):3390-3397.
112. Nikiforov YE, Nikiforova MN. Molecular genetics and diagnosis of thyroid cancer. Nat Rev Endocrinol. 2011;7(10):569-580.
113. Nikiforov YE. Molecular diagnostics of thyroid tumors. Arch Pathol Lab Med. 2011;135(5):569-577.
114. Zhu Z, Gandhi M, Nikiforova MN, Fischer AH, Nikiforov YE. Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma: an unusually high prevalence of ras mutations. Am J Clin Pathol. 2003;120(1):71-77.
115. Adeniran AJ, Zhu Z, Gandhi M, et al. Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas. Am J Surg Pathol. 2006;30(2): 216-222.
116. Nikiforova MN, Nikiforov YE. Molecular diagnostics and predictors in thyroid cancer. Thyroid. 2009;19(12):1351-1361.
117. Pierotti MA, Vigneri P, Bongarzone I. Rearrangements of RET and NTRK1 tyrosine kinase receptors in papillary thyroid carcinomas. Recent Results Cancer Res. 1998;154:237-247.
118. Unger K, Zurnadzhy L, Walch A, et al. RET rearrangements in post-Chernobyl papillary thyroid carcinomas with a short latency analysed by interphase FISH. Br J Cancer. 2006;94(10):1472-1477.
119. Layfield LJ, Morton MJ, Cramer HM, Hirschowitz S. Implications of the proposed thyroid fine-needle aspiration category of "follicular lesion of undetermined significance": a five-year multi-institutional analysis. Diagn Cytopathol. 2009;37(10):710-714.
120. Theoharis C, Roman S, Sosa JA. The molecular diagnosis and management of thyroid neoplasms. Curr Opin Oncol. 2012;24(1):35-41.
121. Thyroid cancer mutation panel (BRAF, RAS, RET/PTC, PAX8/PPAR). Quest Diagnostics Web site. http://www.questdiagnostics.com/hcp/testmenu/jsp/ showTestMenu.jsp?fn=90469.html&labCode=AMD. Accessed August 4, 2012.
122. Chudova D, Wilde JI, Wang ET, et al. Molecular classification of thyroid nodules using high-dimensionality genomic data. J Clin Endocrinol Metab. 2010; 95(12):5296-5304.
123. Ferraz C, Eszlinger M, Paschke R. Current state and future perspective of molecular diagnosis of fine-needle aspiration biopsy of thyroid nodules. J Clin Endocrinol Metab. 2011;96(7):2016-2026.
124. Moses W, Weng J, Sansano I, et al. Molecular testing for somatic mutations improves the accuracy of thyroid fine-needle aspiration biopsy. World J Surg. 2010;34(11):2589-2594.
125. Alexander EK, Kennedy GC, Baloch ZW, et al. Preoperative diagnosis of benign thyroid nodules with indeterminate cytology. N Engl J Med. 2012;367: 705-715.
126. Ljung BM. Thyroid fine-needle aspiration: smears versus liquid-based preparations. Cancer Cytopathol. 2008;114(3):144-148.
127. Fischer AH, Clayton AC, Bentz JS, et al. Performance differences between conventional smears and liquid-based preparations of thyroid FNA samples: analysis of 47,076 responses in the College of American Pathologists interlaboratory comparison program in nongynecologic cytology. Arch Pathol Lab Med. 2013;137(1):26-31.
128. Tan YY, Kebebew E, Reiff E, et al. Does routine consultation of thyroid fine-needle aspiration cytology change surgical management? J Am Coll Surg. 2007;205(1):8-12.
129. Nasuti JF, Gupta PK, Baloch ZW. Diagnostic value and cost-effectiveness of on-site evaluation of fine-needle aspiration specimens: review of 5,688 cases. Diagn Cytopathol. 2002;27(1):1-4.
130. Layfield LJ, Bentz JS, Gopez EV. Immediate on-site interpretation of fineneedle aspiration smears. Cancer Cytopathol. 2001;93:319-322.
131. Wu M, Burstein DE, Yuan S, et al. A comparative study of 200 fine needle aspiration biopsies performed by clinicians and cytopathologists. Laryngoscope. 2006;116(7):1212-1215.
132. Lieu D. Cytopathologist-performed ultrasound-guided fine-needle aspiration and core-needle biopsy: a prospective study of 500 consecutive cases. Diagn Cytopathol. 2008;36(5):317-324.
133. Wu M. A comparative study of 200 head and neck FNAs performed by a cytopathologist with versus without ultrasound guidance: evidence for improved diagnostic value with ultrasound guidance. Diagn Cytopathol. 2011;39(10):743-751.
134. Lieu D. Value of cytopathologist-performed ultrasound-guided fineneedle aspiration as a screening test for ultrasound-guided core-needle biopsy in nonpalpable breast masses. Diagn Cytopathol. 2009;37(4):262-269.
135. Wu M, Chen H, Zheng X, Burstein DE. Evaluation of a scoring system for predicting lymph node malignancy in ultrasound guided fine needle aspiration practice [published online ahead of print June 10, 2011]. Diagn Cytopathol. doi: 10.1002/dc.21745.
136. Porter ME, Teisberg EO. Redefining Health Care. 1st ed. Boston, MA: Harvard Business School Publishing; 2006.